PCN57 Cost Effectiveness of Nilotinib Versus Imatinib as First Line Treatment for Newly Diagnosed Hong Kong (HK) Patients With Chronic Phase, Philadelphia Chromosome-Positive (PH+) Chronic Myeloid Leukemia in the Chronic Phase (CML-CP) in Hong Kong

✍ Scribed by Tse, V.; Liu, H.; Botteman, M.; Mcghee, S.; Lee, V.W.; Lee, K.K.

• Book ID: 122191541
• Publisher: John Wiley and Sons
• Year: 2012
• Tongue: English
• Weight: 73 KB
• Volume: 15
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/j.jval.2012.03.1174